Sedivention Secures €800,000 in Pre-Seed Funding for Novel Obesity Therapy
Deal News | Nov 18, 2024 | High-Tech Gruenderfonds Manage
Sedivention, a German medical technology start-up, has successfully raised €800,000 in pre-seed funding from High-Tech Gründerfonds (HTGF), a prominent early-stage investor in Germany and Europe. The funds will be used to progress the development and initial preclinical studies of Sedivention's innovative medical device. This device is aimed at treating obesity through a one-time, minimally invasive procedure that ablates the gastric branches of the vagus nerve. The procedure is designed to be cost-effective and can be conducted in an outpatient setting, offering a potential breakthrough in treating obesity and its associated comorbidities like diabetes and hypertension. Obesity continues to be a critical global health issue, projected to affect 1.5 billion people by 2030. The funds from HTGF will enable Sedivention to continue product development and preclinical testing to bring this promising therapy closer to clinical trials.
Sectors
- Medical Technology
- Healthcare
- Venture Capital
Geography
- Germany – The start-up Sedivention is based near Munich, and HTGF is a prominent German investor.
- Europe – HTGF is one of the leading early-stage investors in Europe, supporting companies like Sedivention across the region.
Industry
- Medical Technology – Sedivention's innovative device represents a breakthrough in medical technology targeted at obesity treatment.
- Healthcare – The development of Sedivention's medical device addresses significant health concerns related to obesity and associated diseases.
- Venture Capital – HTGF's investment in Sedivention highlights the role of venture capital in funding early-stage medical technology companies.
Financials
- €800,000 – Pre-seed funding amount secured by Sedivention from HTGF.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sedivention GmbH | Target Company | Company | A medical technology start-up focused on developing a minimally invasive therapy for obesity. |
| High-Tech Gründerfonds (HTGF) | Investor | Company | A leading early-stage investor in Germany and Europe, providing funding to start-ups in various technology fields. |
| Dr. Ute Nollert | Founder | Person | Founder of Sedivention, leading the development of the innovative obesity treatment device. |
| Dr. Jan Engels | Investment Manager | Person | Investment Manager at HTGF involved in the funding of Sedivention. |